menu
    • menu

    Company profile for Orphagen Pharmaceuticals

    NEW Drugs in Dev: 2
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Orphagen discovers and develops small molecules to drug targets that have significant unrealized potential in areas of high clinical need. We focus on the unexplored or “orphan” members of the nuclear receptor family. Nuclear receptors have been a rich source of successful drugs. Orphagen has identified drug-like small molecules to several orphan nuclear receptors and has described efficacy in animal models of disease. An...
    Orphagen discovers and develops small molecules to drug targets that have significant unrealized potential in areas of high clinical need. We focus on the unexplored or “orphan” members of the nuclear receptor family. Nuclear receptors have been a rich source of successful drugs. Orphagen has identified drug-like small molecules to several orphan nuclear receptors and has described efficacy in animal models of disease. An early success led to a partnership with Japan Tobacco (JT) Pharma to discover and develop oral drugs to treat psoriasis and other autoimmune diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Orphagen PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    11558 Sorrento Valley Rd., Suite 4 San Diego, CA 92121
    Telephone
    Telephone
    (858) 481-6191
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.orphagen.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/orphagenpharmaceuticals/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Natural Product Expo West

    Natural Product Expo West

    Not Confirmed

    envelop Contact Supplier

    Natural Product Expo West

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Orphagen Pharma Receives NIH Grant to Advance IBD Drug
    Orphagen Pharma Receives NIH Grant to Advance IBD Drug

    09 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241209551628/en

    BUSINESSWIRE
    09 Dec 2024
    Share Share
    Orphagen Pharma Receives Rare Pediatric Disease Designation from FDA for OR-449
    Orphagen Pharma Receives Rare Pediatric Disease Designation from FDA for OR-449

    17 Jan 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230117005036/en

    BUSINESSWIRE
    17 Jan 2023
    Share Share
    Orphagen Pharma Presents Data on Downstream Targets of SF-1 Antagonist OR-449
    Orphagen Pharma Presents Data on Downstream Targets of SF-1 Antagonist OR-449

    11 Jun 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220611005002/en

    BUSINESSWIRE
    11 Jun 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search